AMGN - Amgen Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—General
Thousand Oaks,
United States
Type: Equity
AMGN price evolution
AMGN
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10944 | $34741 | $34248 | $31560 |
| Short term investments | $1 | |||
| Net receivables | $7268 | $6145 | $5830 | $5736 |
| Inventory | $9518 | $5026 | $4978 | $5011 |
| Total current assets | $30332 | $48477 | $47380 | $44703 |
| Long term investments | ||||
| Property, plant & equipment | $5941 | $5563 | $5532 | $5460 |
| Goodwill & intangible assets | $51270 | $28659 | $30164 | $30924 |
| Total noncurrent assets | $66822 | $42057 | $42889 | $44017 |
| Total investments | $1 | |||
| Total assets | $97154 | $90534 | $90269 | $88720 |
| Current liabilities | ||||
| Accounts payable | $1590 | $1358 | $1212 | $1320 |
| Deferred revenue | ||||
| Short long term debt | $1443 | $1428 | $2167 | $834 |
| Total current liabilities | $18392 | $16954 | $17097 | $14215 |
| Long term debt | $63170 | $59040 | $59377 | $60761 |
| Total noncurrent liabilities | $72530 | $65924 | $66391 | $69157 |
| Total debt | $64613 | $60468 | $61544 | $61595 |
| Total liabilities | $90922 | $82878 | $83488 | $83372 |
| Shareholders' equity | ||||
| Retained earnings | -$26549 | -$24971 | -$25540 | -$26919 |
| Other shareholder equity | -$289 | -$126 | -$280 | -$268 |
| Total shareholder equity | $6232 | $7656 | $6781 | $5348 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10944 | $7629 | $7989 | $6266 |
| Short term investments | $1676 | $48 | $4381 | |
| Net receivables | $7268 | $5563 | $4895 | $4525 |
| Inventory | $9518 | $4930 | $4086 | $3893 |
| Total current assets | $30332 | $22186 | $19385 | $21144 |
| Long term investments | $1176 | |||
| Property, plant & equipment | $5941 | $5427 | $5184 | $4889 |
| Goodwill & intangible assets | $51270 | $31609 | $30072 | $31276 |
| Total noncurrent assets | $66822 | $42935 | $41780 | $41804 |
| Total investments | $1676 | $48 | $4381 | |
| Total assets | $97154 | $65121 | $61165 | $62948 |
| Current liabilities | ||||
| Accounts payable | $1590 | $14096 | $1366 | $1421 |
| Deferred revenue | ||||
| Short long term debt | $1443 | $1591 | $87 | $91 |
| Total current liabilities | $18392 | $15687 | $12184 | $11653 |
| Long term debt | $63170 | $37354 | $33222 | $32895 |
| Total noncurrent liabilities | $72530 | $45773 | $42281 | $41886 |
| Total debt | $64613 | $38945 | $33309 | $32986 |
| Total liabilities | $90922 | $61460 | $54465 | $53539 |
| Shareholders' equity | ||||
| Retained earnings | -$26549 | -$28622 | -$24600 | -$21408 |
| Other shareholder equity | -$289 | $3661 | -$796 | -$985 |
| Total shareholder equity | $6232 | $3661 | $6700 | $9409 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6903 | $6986 | $6105 | |
| Cost of revenue | $1806 | $1813 | $1720 | |
| Gross Profit | $5097 | $5173 | $4385 | |
| Operating activities | ||||
| Research & development | $1079 | $1113 | $1058 | |
| Selling, general & administrative | $1353 | $1294 | $1258 | |
| Total operating expenses | $3076 | $2489 | $2464 | |
| Operating income | $2021 | $2684 | $1921 | |
| Income from continuing operations | ||||
| EBIT | $2706 | $2366 | $3985 | |
| Income tax expense | $217 | $235 | $601 | |
| Interest expense | $759 | $752 | $543 | |
| Net income | ||||
| Net income | $1730 | $1379 | $2841 | |
| Income (for common shares) | $1730 | $1379 | $2841 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $28190 | $26323 | $25979 | $25424 |
| Cost of revenue | $8451 | $6406 | $6454 | $6159 |
| Gross Profit | $19739 | $19917 | $19525 | $19265 |
| Operating activities | ||||
| Research & development | $4784 | $4434 | $4819 | $4207 |
| Selling, general & administrative | $6179 | $5414 | $5368 | $5730 |
| Total operating expenses | $11842 | $10351 | $11886 | $10126 |
| Operating income | $7897 | $9566 | $7639 | $9139 |
| Income from continuing operations | ||||
| EBIT | $10730 | $8752 | $7898 | $9395 |
| Income tax expense | $1138 | $794 | $808 | $869 |
| Interest expense | $2875 | $1406 | $1197 | $1262 |
| Net income | ||||
| Net income | $6717 | $6552 | $5893 | $7264 |
| Income (for common shares) | $6717 | $6552 | $5893 | $7264 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $767 | $1730 | $1379 | $2841 |
| Operating activities | ||||
| Depreciation | $1380 | $895 | $896 | $900 |
| Business acquisitions & disposals | -$26989 | |||
| Stock-based compensation | $431 | |||
| Total cash flows from operations | $538 | $2760 | $4109 | $1064 |
| Investing activities | ||||
| Capital expenditures | -$249 | -$248 | -$271 | -$344 |
| Investments | -$2 | -$1 | $1 | $1674 |
| Total cash flows from investing | -$27089 | -$262 | -$211 | $1358 |
| Financing activities | ||||
| Dividends paid | -$1140 | -$1140 | -$1139 | -$1137 |
| Sale and purchase of stock | ||||
| Net borrowings | $3899 | -$879 | -$18 | $22674 |
| Total cash flows from financing | $2754 | -$2005 | -$1210 | $21509 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$23797 | $493 | $2688 | $23931 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $6717 | $6552 | $5893 | $7264 |
| Operating activities | ||||
| Depreciation | $4071 | $3417 | $3398 | $3601 |
| Business acquisitions & disposals | -$26989 | -$3709 | -$2529 | |
| Stock-based compensation | $431 | $401 | $341 | $330 |
| Total cash flows from operations | $8471 | $9721 | $9261 | $10497 |
| Investing activities | ||||
| Capital expenditures | -$1112 | -$936 | -$880 | -$608 |
| Investments | $1672 | -$1387 | $4177 | -$4718 |
| Total cash flows from investing | -$26204 | -$6044 | $733 | -$5401 |
| Financing activities | ||||
| Dividends paid | -$4556 | -$4196 | -$4013 | -$3755 |
| Sale and purchase of stock | -$6360 | -$4975 | -$3486 | |
| Net borrowings | $25676 | $6622 | $795 | $2464 |
| Total cash flows from financing | $21048 | -$4037 | -$8271 | -$4867 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $3315 | -$360 | $1723 | $229 |
News
|
AbbVie retains Humira market despite copycats (NYSE:ABBV)
Seeking Alpha
13 Apr 2024
|
|
Merck, Vertex could beat expectations despite more subdued 1Q biopharma earnings anticipated: BofA...
Investing.com
12 Apr 2024
|
|
Insiders are Piling into These 10 Healthcare Stocks in 2024
Insider Monkey via Yahoo Finance
10 Apr 2024
|
|
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper...
MarketWatch via Yahoo Finance
10 Apr 2024
|
|
11 Best Biotech ETFs To Buy
Insider Monkey via Yahoo Finance
9 Apr 2024
|
|
Morgan Stanley sees Fed rate cut fueling biotech stocks (NYSE:MRK)
Seeking Alpha
7 Apr 2024
|
|
10 Best Weight Loss Drug Stocks to Buy Now
Insider Monkey via Yahoo Finance
7 Apr 2024
|
|
13 Best Cheap Dividend Stocks To Buy Right Now
Insider Monkey via Yahoo Finance
6 Apr 2024
|
|
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Zacks via Yahoo Finance
5 Apr 2024
|
|
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
Zacks via Yahoo Finance
5 Apr 2024
|
Fundamentals
| Market cap | $142.15B |
|---|---|
| Enterprise value | $195.82B |
| Shares outstanding | 535.40M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 21.80 |
| Book/Share | 12.18 |
| Cash/Share | 20.44 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 14.59 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.65 |
| Quick ratio | 1.13 |